| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
DHR Stock Overview
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.
Danaher Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$280.45 |
| 52 Week High | US$333.96 |
| 52 Week Low | US$211.22 |
| Beta | 0.70 |
| 1 Month Change | -12.58% |
| 3 Month Change | -8.38% |
| 1 Year Change | 17.82% |
| 3 Year Change | 163.75% |
| 5 Year Change | 246.41% |
| Change since IPO | 28,849.68% |
Recent News & Updates
Danaher (NYSE:DHR) Has A Rock Solid Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Here's Why I Think Danaher (NYSE:DHR) Is An Interesting Stock
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
Danaher: A Jewel In The Crown
A number of subsidiaries are involved with the expanding market of biopharmaceuticals. Whilst it is true that revenue is growing for the Life Sciences division, it is not gaining market share. Danaher’s competitors are gaining.
Shareholder Returns
| DHR | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -4.4% | -4.7% | -6.1% |
| 1Y | 17.8% | 1.8% | 4.2% |
Return vs Industry: DHR exceeded the US Life Sciences industry which returned 1.8% over the past year.
Return vs Market: DHR exceeded the US Market which returned 4.2% over the past year.
Price Volatility
| DHR volatility | |
|---|---|
| DHR Average Weekly Movement | 3.8% |
| Life Sciences Industry Average Movement | 9.1% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.4% |
Stable Share Price: DHR is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: DHR's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1969 | 68,000 | Rainer Blair | https://www.danaher.com |
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Danaher Fundamentals Summary
| DHR fundamental statistics | |
|---|---|
| Market Cap | US$200.40b |
| Earnings (TTM) | US$5.64b |
| Revenue (TTM) | US$28.07b |
35.6x
P/E Ratio7.1x
P/S RatioIs DHR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DHR income statement (TTM) | |
|---|---|
| Revenue | US$28.07b |
| Cost of Revenue | US$11.02b |
| Gross Profit | US$17.05b |
| Expenses | US$11.41b |
| Earnings | US$5.64b |
Last Reported Earnings
Oct 01, 2021
Next Earnings Date
Jan 27, 2022
| Earnings per share (EPS) | 7.89 |
| Gross Margin | 60.75% |
| Net Profit Margin | 20.08% |
| Debt/Equity Ratio | 54.3% |
How did DHR perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield10%
Payout RatioValuation
Is Danaher undervalued compared to its fair value and its price relative to the market?
2.5%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: DHR ($280.45) is trading below our estimate of fair value ($287.63)
Significantly Below Fair Value: DHR is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: DHR is good value based on its PE Ratio (35.6x) compared to the US Life Sciences industry average (39.3x).
PE vs Market: DHR is poor value based on its PE Ratio (35.6x) compared to the US market (16.5x).
Price to Earnings Growth Ratio
PEG Ratio: DHR is poor value based on its PEG Ratio (5.7x)
Price to Book Ratio
PB vs Industry: DHR is overvalued based on its PB Ratio (5x) compared to the US Life Sciences industry average (3.2x).
Future Growth
How is Danaher forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
6.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DHR's forecast earnings growth (6.3% per year) is above the savings rate (2%).
Earnings vs Market: DHR's earnings (6.3% per year) are forecast to grow slower than the US market (13% per year).
High Growth Earnings: DHR's earnings are forecast to grow, but not significantly.
Revenue vs Market: DHR's revenue (6% per year) is forecast to grow slower than the US market (9.1% per year).
High Growth Revenue: DHR's revenue (6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DHR's Return on Equity is forecast to be low in 3 years time (13%).
Past Performance
How has Danaher performed over the past 5 years?
18.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DHR has high quality earnings.
Growing Profit Margin: DHR's current net profit margins (20.1%) are higher than last year (15.1%).
Past Earnings Growth Analysis
Earnings Trend: DHR's earnings have grown by 18.5% per year over the past 5 years.
Accelerating Growth: DHR's earnings growth over the past year (82.9%) exceeds its 5-year average (18.5% per year).
Earnings vs Industry: DHR earnings growth over the past year (82.9%) exceeded the Life Sciences industry 72.2%.
Return on Equity
High ROE: DHR's Return on Equity (13.3%) is considered low.
Financial Health
How is Danaher's financial position?
Financial Position Analysis
Short Term Liabilities: DHR's short term assets ($10.8B) exceed its short term liabilities ($7.3B).
Long Term Liabilities: DHR's short term assets ($10.8B) do not cover its long term liabilities ($31.8B).
Debt to Equity History and Analysis
Debt Level: DHR's net debt to equity ratio (48.4%) is considered high.
Reducing Debt: DHR's debt to equity ratio has increased from 36.1% to 54.3% over the past 5 years.
Debt Coverage: DHR's debt is well covered by operating cash flow (34.9%).
Interest Coverage: DHR's interest payments on its debt are well covered by EBIT (31.5x coverage).
Balance Sheet
Dividend
What is Danaher current dividend yield, its reliability and sustainability?
0.30%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: DHR's dividend (0.3%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.37%).
High Dividend: DHR's dividend (0.3%) is low compared to the top 25% of dividend payers in the US market (3.6%).
Stability and Growth of Payments
Stable Dividend: DHR is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: DHR is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: DHR is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DHR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.1yrs
Average management tenure
CEO
Rainer Blair (57 yo)
1.33yrs
Tenure
US$10,396,761
Compensation
Mr. Rainer M. Blair serves as President, Chief Executive Officer and Director at Danaher Corporation since September 1, 2020. Mr. Blair served as an Executive Vice President of Danaher Corporation since Ja...
CEO Compensation Analysis
Compensation vs Market: Rainer's total compensation ($USD10.40M) is about average for companies of similar size in the US market ($USD11.47M).
Compensation vs Earnings: Rainer's compensation has increased by more than 20% in the past year.
Leadership Team
Experienced Management: DHR's management team is considered experienced (4.1 years average tenure).
Board Members
Experienced Board: DHR's board of directors are seasoned and experienced ( 14.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DHR insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Danaher Corporation's employee growth, exchange listings and data sources
Key Information
- Name: Danaher Corporation
- Ticker: DHR
- Exchange: NYSE
- Founded: 1969
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$200.403b
- Shares outstanding: 714.58m
- Website: https://www.danaher.com
Number of Employees
Location
- Danaher Corporation
- 2200 Pennsylvania Avenue, NW
- Suite 800W
- Washington
- District Of Columbia
- 20037-1701
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/01/23 23:07 |
| End of Day Share Price | 2022/01/21 00:00 |
| Earnings | 2021/10/01 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.